C2729 / C2729-M

Test Code C2729 / C2729-M 
Test CA 27.29 (BREAST), SERUM 
Methodology Chemiluminometric Immunoassay 
Description Useful For:
The Food and Drug Administration has approved CA 27.29 for serial testing in women with prior stage II or III breast cancer who are clinically free of disease.

Predicting early recurrence of disease in women with treated carcinoma of the breast

As an indication that additional tests or procedures should be performed to confirm recurrence of breast cancer

NOTE: This test, when ordered on Medicare patients, is subject to the National Coverage Determination (NCD) policy "Tumor Antigen by Immunoassay CA 15-3/CA 27.29". Please verify that the diagnosis code (ICD-9) you have chosen demonstrates medical necessity for the test as documented in the physician's patient record. The CMS web site or the NorDx Limited Coverage Documentation Guide are available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD-9 code chosen. 

Specimen Draw blood in a serum gel tube or plain red top tube. Spin down and send 0.5 mL (minimum volume: 0.25 mL) of serum refrigerated in a screw-capped, plastic vial.

**Freeze if not processed within 7 days**

1. Serum gel tubes should be centrifuged within 2 hours of collection.

2. Red-top tubes should be centrifuged and aliquoted within 2 hours of collection 

Reference Values Males
> or =18 years: < or =38.0 U/mL (use not defined)

> or =18 years: < or =38.0 U/mL

Reference values have not been established for patients who are <18 years of age.

Serum markers are not specific for malignancy, and values may vary by method. 

Analytic Time 1 Day 
Day(s) Test Set Up Monday through Friday 
CPT Code(s) 86300